Literature DB >> 10500955

[Risk factor of liver disorders caused by flutamide--statistical analysis using multivariate logistic regression analysis].

T Wada1, M Ueda, K Abe, T Kobari, H Yamazaki, J Nakata, I Ikemoto, Y Ohishi, Y Aizawa.   

Abstract

The antiandrogenic drug, flutamide (Odyne), is widely used in the treatment of carcinoma of prostate. It is well known that flutamide has adverse effects of liver disorders. To ascertain the risk of liver disorders before administering this drug, past history and lifestyle preferences were resurveyed in 123 patients who had been treated with flutamide. The results obtained were assessed in relation to the occurrence of liver disorders by multivariate logistic regression analysis. The incidence of liver disorders was 26% (33/123), with 64% of the disorders occurring within 9 months. The chi-square test for dependent variables revealed that three variables, i.e., body mass index, past history of liver disorders and elevated glutamic-pyruvic transaminase levels were significantly related to the incidence of liver disorders (p > 0.05). Multivariate analysis indicated that a history of liver disorders and elevated alanine aminotransferase (ALT) levels were related to a higher incidence of liver disorders. Elevated ALT levels were associated with a higher incidence of liver disorders and smoking was related to a lower incidence of the liver disorders.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10500955

Source DB:  PubMed          Journal:  Hinyokika Kiyo        ISSN: 0018-1994


  3 in total

Review 1.  Dose adaptation of antineoplastic drugs in patients with liver disease.

Authors:  Lydia Tchambaz; Chantal Schlatter; Max Jakob; Anita Krähenbühl; Peter Wolf; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 2.  Roles of Cofactors in Drug-Induced Liver Injury: Drug Metabolism and Beyond.

Authors:  Ruizhi Gu; Alina Liang; Grace Liao; Isabelle To; Amina Shehu; Xiaochao Ma
Journal:  Drug Metab Dispos       Date:  2022-02-27       Impact factor: 3.579

3.  Flutamide-induced hepatic dysfunction in relation to steady-state plasma concentrations of flutamide and its metabolites.

Authors:  Yoshio Aizawa; Isao Ikemoto; Koichi Kishimoto; Tetsuro Wada; Haruki Yamazaki; Yukihiko Ohishi; Hiroshi Kiyota; Nozomu Furuta; Hidenori Suzuki; Masataka Ueda
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.842

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.